VTE (VENOUS THROMBOEMBOLISM)
Clinical trials for VTE (VENOUS THROMBOEMBOLISM) explained in plain language.
Never miss a new study
Get alerted when new VTE (VENOUS THROMBOEMBOLISM) trials appear
Sign up with your email to follow new studies for VTE (VENOUS THROMBOEMBOLISM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a Once-Daily pill prevent deadly clots in cancer patients?
Disease control Recruiting nowThis study compares two different dosing schedules of the blood thinner apixaban (Eliquis) against no blood thinner in about 996 cancer patients at moderate risk for blood clots. Participants take either 2.5 mg twice daily, 5 mg once daily, or no anticoagulant for 6 months. The g…
Matched conditions: VTE (VENOUS THROMBOEMBOLISM)
Phase: PHASE3 • Sponsor: University of Vermont • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Pill vs. needle: can Lower-Dose blood thinners protect blood cancer patients from deadly clots?
Disease control Recruiting nowThis study compares two types of blood thinners taken as pills (apixaban and rivaroxaban) against a standard daily injection (enoxaparin) to prevent dangerous blood clots in people with blood cancers like lymphoma, leukemia, and multiple myeloma. About 100 participants will be ra…
Matched conditions: VTE (VENOUS THROMBOEMBOLISM)
Phase: NA • Sponsor: Medical University of Gdansk • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC